Literature DB >> 2156153

Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1.

J Balzarini1, E De Clercq, H Baumgartner, M Bodenteich, H Griengl.   

Abstract

The (+)- and (-)-enantiomers of the carbocyclic analogues of (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) and 5-iodo-2'-deoxyuridine (C-IDU) were synthesized by separate routes. Both the (+)- and (-)-enantiomers of C-BVDU and C-IDU were markedly inhibitory to herpes simplex virus type 1 (HSV-1) replication. (+)-C-BVDU and (+)-C-IDU were as inhibitory to HSV-1 as the racemic (+/-)-C-BVDU and (+/-)-C-IDU, respectively, whereas the (-)-enantiomers were only 10-fold less active. Also, the (+)- and (-)-enantiomers of C-BVDU were equally inhibitory to the growth of murine mammary carcinoma cells transformed by the HSV-1 or HSV-2 thymidine kinase (TK) gene (designated FM3A TK-/HSV-1 TK+ and FM3A TK-/HSV-2 TK+). The (+)- and (-)-enantiomers of C-BVDU and the (+)- and (-)-enantiomers of C-IDU had a remarkably similar affinity for HSV-1 TK [Ki, 0.09 and 0.19 microM for (+)-C-BVDU and (+)-C-IDU and 0.16 and 0.19 microM for (-)-C-BVDU and (-)-C-IDU, respectively]. The inhibition of HSV-1 TK by BVDU, IDU, (+)-C-BVDU, and (+)-C-IDU was purely competitive with regard to the natural substrate (thymidine), whereas (-)-C-BVDU, (-)-C-IDU, (+/-)-C-BVDU, and (+/-)C-IDU showed a linear mixed-type inhibition of HSV-1 TK. C-BVDU and C-IDU are examples of chiral molecules of which both isomeric forms are markedly active at both the cellular and enzymatic level.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156153

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Anti-(herpes simplex virus) activity of 4'-thio-2'-deoxyuridines: a biochemical investigation for viral and cellular target enzymes.

Authors:  A Verri; F Focher; R J Duncombe; I Basnak; R T Walker; P L Coe; E de Clercq; G Andrei; R Snoeck; J Balzarini; S Spadari
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.

Authors:  J A Coates; N Cammack; H J Jenkinson; I M Mutton; B A Pearson; R Storer; J M Cameron; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  L-ATP is recognized by some cellular and viral enzymes: does chance drive enzymic enantioselectivity?

Authors:  A Verri; A Montecucco; G Gosselin; V Boudou; J L Imbach; S Spadari; F Focher
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

4.  Metabolism in human cells of the D and L enantiomers of the carbocyclic analog of 2'-deoxyguanosine: substrate activity with deoxycytidine kinase, mitochondrial deoxyguanosine kinase, and 5'-nucleotidase.

Authors:  L L Bennett; P W Allan; G Arnett; Y F Shealy; D S Shewach; W S Mason; I Fourel; W B Parker
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  The effect of substrate binding on the conformation and structural stability of Herpes simplex virus type 1 thymidine kinase.

Authors:  C Wurth; U Kessler; J Vogt; G E Schulz; G Folkers; L Scapozza
Journal:  Protein Sci       Date:  2001-01       Impact factor: 6.725

6.  Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues.

Authors:  A Verri; G Priori; S Spadari; L Tondelli; F Focher
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

Review 7.  Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review.

Authors:  T Kulikowski
Journal:  Pharm World Sci       Date:  1994-04-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.